Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino… - Jama, 2018 - jamanetwork.com
Importance Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal
premature aging disease. There is no approved treatment. Objective To evaluate the …
保存ほぞん 引用いんよう 被ひ引用いんよう数すう: 199 関連かんれん記事きじ
[HTML] nih.gov

[HTML][HTML] Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - ncbi.nlm.nih.gov
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With
Hutchinson-Gilford Progeria Syndrome - PMC Back to Top Skip to main content NIH NLM Logo …
引用いんよう
[PDF] eigerbio.com

[PDF][PDF] Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - eigerbio.com
OBJECTIVE To evaluate the association of monotherapy using the protein
farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS. DESIGN …
引用いんよう

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Importance Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal
premature aging disease. There is no approved treatment. Objective To evaluate the …
引用いんよう

[引用いんよう][C] Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino… - JAMA, 2018 - cir.nii.ac.jp
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With
Hutchinson-Gilford Progeria Syndrome | CiNii Research CiNii 国立こくりつ情報じょうほう学がく研究所けんきゅうじょ 学術がくじゅつ情報じょうほう …
引用いんよう

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - europepmc.org
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With
Hutchinson-Gilford Progeria Syndrome. - Abstract - Europe PMC Sign in | Create an account …
引用いんよう
[PDF] eigerbio.com

[PDF][PDF] Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - eigerbio.com
OBJECTIVE To evaluate the association of monotherapy using the protein
farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS. DESIGN …
引用いんよう

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - europepmc.org
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With
Hutchinson-Gilford Progeria Syndrome. - Abstract - Europe PMC Sign in | Create an account …
引用いんよう
[PDF] eigerbio.com

[PDF][PDF] Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

LB Gordon, H Shappell, J Massaro, RB D'Agostino Sr… - JAMA, 2018 - eigerbio.com
OBJECTIVE To evaluate the association of monotherapy using the protein
farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS. DESIGN …
引用いんよう